Carmine Muto

Carmine Muto

Auto-generated profile, based on publicly available information

Carmine Muto

Ospedale S. Maria della Pietà, Nola, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
CMCarmine Muto
Carmine Muto
FSFrancesco Solimene
Francesco Solimene
PGPaolo Gallo
Paolo Gallo
MNMaurizio Nastasi
Maurizio Nastasi
CRConcetto La Rosa
Concetto La Rosa
BTBernardino Tuccillo
Bernardino Tuccillo
Background—: Current recommendations require a QRS duration of ≥120 ms as a condition for prescribing cardiac resynchronization therapy (CRT). This study was designed to test the hypothesis that patients with heart failure (HF) of ischemic origin, current indications for defibrillator implantation, and QRS <120 ms may benefit from CRT in the presence of marked mechanical dyssynchrony. Methods and Results—: Patients with intraventricular dyssynchrony on echocardiography were randomly assigned to CRT or dual-chamber defibrillator implantation (CRT defibrillator and dual-chamber implantable cardioverter-defibrillator arm, respectively). The primary end point was the HF clinical composite response, which scores patients as improved, unchanged, or worsened. The secondary end point was the cumulative survival from HF hospitalization and HF death. An additional secondary end point was the composite of HF hospitalization, HF death, and spontaneous ventricular fibrillation. Twenty-three of 56 patients with CRT defibrillator showed an improvement in their clinical composite response at 1 year, compared with 9 of 55 patients with dual-chamber implantable cardioverter-defibrillator (41% versus 16%; P =0.004). After a median follow-up of 16 months, the CRT defibrillator arm showed a nonsignificant higher survival from HF hospitalization and HF death ( P =0.077), and a significantly higher survival from the combined end point of HF hospitalization, HF death, and spontaneous ventricular fibrillation ( P =0.028). Conclusions—: In this comparison of CRT defibrillator and dual-chamber implantable cardioverter-defibrillator, CRT improved clinical status in some patients with ischemic cardiomyopathy, mild-to-moderate symptoms, narrow QRS duration, and mechanical dyssynchrony on echocardiography. Clinical Trial Registration—: URL: http://clinicaltrials.gov . Unique identifier: NCT01577446.

1 November 2010 in Heart Rhythm
Verified
Journal Article
Closed access
CMCarmine Muto
Carmine Muto
MGMaurizio Gasparini
Maurizio Gasparini
CNCarlo Peraldo Neja
Carlo Peraldo Neja
SISaverio Iacopino
Saverio Iacopino
MDMario Davinelli
Mario Davinelli
BTBernardino Tuccillo
Bernardino Tuccillo

1 March 2012 in American Heart Journal
Verified
Journal Article
Closed access
MGMaurizio Gasparini
Maurizio Gasparini
CMCarmine Muto
Carmine Muto
Saverio IacopinoSaverio Iacopino
Saverio Iacopino
FZFrancesco Zanon
Francesco Zanon
CDCosimo Dicandia
Cosimo Dicandia
ADAlessandra Denaro
Alessandra Denaro

30 September 2008 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
PDF file
LALuigi Ascione
Luigi Ascione
CMCarmine Muto
Carmine Muto
RIRaffaele Iengo
Raffaele Iengo
ECEduardo Celentano
Eduardo Celentano
MAMaria Accadia
Maria Accadia
BTBernardino Tuccillo
Bernardino Tuccillo

28 June 2008 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
BTBernardino Tuccillo
Bernardino Tuccillo
CMCarmine Muto
Carmine Muto
RIRaffaele Iengo
Raffaele Iengo
MAMaria Accadia
Maria Accadia
SRSalvatore Rumolo
Salvatore Rumolo
LALuigi Ascione
Luigi Ascione

22 May 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CMCarmine Muto
Carmine Muto
VCValeria Calvi
Valeria Calvi
GBGiovanni Luca Botto
Giovanni Luca Botto
DPDomenico Pecora
Domenico Pecora
DPDaniele Porcelli
Daniele Porcelli
GMGiampiero Maglia
Giampiero Maglia
Objective. The aim of the study was to compare the two approaches to chronic right ventricular pacing currently adopted in clinical practice: right ventricular apical (RVA) and non-RVA pacing. Background. Chronic RVA pacing is associated with an increased risk of atrial fibrillation, morbidity, and even mortality. Non-RVA pacing may yield more physiologic ventricular activation and provide potential long-term benefits and has recently been adopted as standard procedure at many implanting centers. Methods. The Right Pace study was a multicenter, prospective, single-blind, nonrandomized trial involving 437 patients indicated for dual-chamber pacemaker implantation with a high percentage of RV pacing. Results. RV lead-tip target location was the apex or the interventricular septum. RVA (274) and non-RVA patients (163) did not differ in baseline characteristics. During a median follow-up of 19 months (25th–75th percentiles, 13–25), 17 patients died. The rates of the primary outcome of death due to any cause or hospitalization for heart failure were comparable between the groups (log-rank test, p=0.609), as were the rates of the composite of death due to any cause, hospitalization for heart failure, or an increase in left ventricular end-systolic volume ≥ 15% as compared with the baseline evaluation (secondary outcome, p=0.703). After central adjudication of X-rays, comparison between adjudicated RVA (239 patients) and non-RVA (170 patients) confirmed the absence of difference in the rates of primary (p=0.402) and secondary (p=0.941) outcome. Conclusions. In patients with indications for dual-chamber pacemaker who require a high percentage of ventricular stimulation, RVA or non-RVA pacing resulted in comparable outcomes. This study is registered with ClinicalTrials.gov (identifier: NCT01647490).